Drug Details
| General Information of the Drug (ID: DR8799) | ||||
|---|---|---|---|---|
| Name |
Radiation
|
|||
| Disease | Breast cancer [ICD-11: 2C60] | Phase 2 | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Alpha lipoic acid | Spinacia oleracea | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Induction | Apoptosis | ||||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers. | |||||
| Noscapine | Papaver somniferum | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Up-regulation | Apoptosis | ||||
| In-vitro Model | T98G | CVCL_0556 | Glioblastoma | Homo sapiens | ||
| GL261 | CVCL_Y003 | Mouse glioblastoma | Mus musculus | |||
| Murine endothelial cell line 2H11 | Healthy | Rattus norvegicus | ||||
| In-vivo Model | For a xenograft model, 2.0 * 106 GL261 cells were injected subcutaneously in the hind limof mice. | |||||
| Experimental
Result(s) |
Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. | |||||
| Vicenin-2 | Urtica circularis | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | RAD50 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H23 | CVCL_1547 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
VCN 2 sensitizes NCI H23 cells to radiation. | |||||
| Vinblastine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Experimental
Result(s) |
Low-dose chemotherapy with methotrexate and vinblastine for 1 year was effective and well tolerated by adult patients with aggressive, recurrent fibromatosis. | |||||
